EQT sets stage for multibillion-pound IPO of IVC Evidensia, shaking up UK markets

EQT AB is preparing a multibillion-pound IPO for veterinary services group IVC Evidensia, marking one of the biggest UK healthcare listings in years, according to The Financial Times. The move could reshape London IPOs, offering a rare opportunity for institutional investors to access a PE-backed healthcare IPO with strong growth and scale.

London IPOs set sights on big revival

The UK’s capital markets have seen a lull in mega-listings, with most PE exits relying on secondary sales. The EQT IPO of IVC Evidensia could signal a European public market revival, showing that large-scale private equity exits can succeed in London. Market analysts say investor appetite is high for private equity-backed healthcare companies, such as veterinary services.

IVC Evidensia targets multibillion-pound valuation

IVC Evidensia operates over 1,800 practices across Europe, providing consistent revenue growth and healthy margins. The IVC Evidensia listing could achieve a multibillion-pound valuation, making it one of the largest veterinary services M&A exits in recent history. The company has grown through strategic acquisitions, consolidating a fragmented market while enhancing operational efficiency.

Market context, investor insights, and sector trends

Analysts say the IPO could attract a wide spectrum of investors, from long-only institutional funds to hedge funds seeking healthcare exposure. “Veterinary services are remarkably resilient to economic cycles, and IVC Evidensia has demonstrated strong revenue predictability,” said one London-based fund manager. “This listing offers a rare combination of scale, growth, and defensive qualities.”

The IPO is also expected to shine a spotlight on private equity-backed healthcare models. Over the past decade, PE firms have increasingly consolidated fragmented healthcare sectors — from hospitals to specialty clinics — to create scalable, cash-generative businesses. IVC Evidensia is now a case study in how such strategies can translate into successful public market entries.

European regulators are closely watching the listing, particularly regarding pricing transparency in veterinary care. While some investors have expressed caution, market participants largely view regulatory hurdles as manageable. “The structure of the IPO and IVC Evidensia’s governance framework should satisfy both regulators and institutional investors,” said a banking analyst involved in healthcare deals.

The IPO could also set benchmarks for future European private equity exits. If successful, it may encourage other PE sponsors in healthcare and adjacent sectors to consider London as a viable listing venue instead of relying on secondary trades or cross-border exits. This has broader implications for the UK capital markets, potentially reviving interest in large-scale IPOs after years of subdued activity.

From an operational perspective, IVC Evidensia’s integration of newly acquired clinics has demonstrated its ability to achieve synergies, improve margins, and standardize care quality — key factors for long-term investor confidence. The company is also exploring digital platforms and telemedicine for pets, which could further enhance its growth profile.

Market observers note that this IPO represents a convergence of several trends: the resilience of healthcare services, the scale of PE consolidation, and a renewed appetite for defensive growth assets in public markets. Institutional investors, especially those seeking ESG-compliant opportunities, are expected to respond favorably to the listing, as veterinary services meet both social and environmental impact criteria indirectly through animal health and welfare.

PE-backed healthcare IPO could set industry benchmark

Private equity firms increasingly view public listings as the ultimate liquidity event. The IPO would represent a major European private equity exit, offering a case study for other PE-backed healthcare companies considering public markets. Regulatory considerations, such as veterinary pricing rules, are closely monitored by investors but are not expected to derail the offering.

Investor outlook and market impact

Institutional investors are closely watching the IPO for both yield and ESG appeal. The listing could encourage other European PE sponsors to test public markets, potentially driving more high-profile exits. Analysts highlight that the EQT IPO could become a bellwether for London’s ability to host large-scale, healthcare-focused IPOs.

Conclusion

With a planned multibillion-pound valuation, IVC Evidensia’s IPO is poised to reshape the UK private equity and public market landscape, offering investors a rare mix of scale, resilience, and growth in the healthcare sector.